Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Plasma Thbs1 As A Predictive Biomarker For Poor Prognosis And Brain Metastasis In Patients With Her2-enriched Breast Cancer.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Plasma Thbs1 As A Predictive Biomarker For Poor Prognosis And Brain Metastasis In Patients With Her2-enriched Breast Cancer.

Related Experiment Video

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer.

Yang Li¹, Jun Qin¹, Guiming Chen¹

¹Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Hongkou District, Shanghai, 200080, China.

International Journal of Clinical Oncology

|February 27, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Plasma thrombospondin-1 (THBS1) shows potential as an unfavorable prognostic marker for HER2-enriched breast cancer. High THBS1 levels correlate with shorter survival and increased brain metastasis risk in this specific patient group.

Keywords:

Brain metastasis Breast cancer Disseminated tumor cells Prognostic marker

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

Related Experiment Videos

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

Area of Science:

Oncology
Biochemistry

Background:

Thrombospondin-1 (THBS1) is a glycoprotein implicated in various cancers, including breast cancer.
The prognostic value of plasma THBS1 in breast cancer remains unclear.

Purpose of the Study:

To investigate the clinical significance of plasma THBS1 levels in breast cancer patients.
To determine the prognostic role of plasma THBS1 in relation to clinicopathological characteristics and survival outcomes.

Main Methods:

Plasma THBS1 levels were quantified using enzyme-linked immunosorbent assay in 627 breast cancer patients.
Disseminated tumor cells (DTCs) were detected in bone marrow aspirates.
Correlation with clinicopathological features and survival prediction was analyzed.

Main Results:

Thrombospondin-1

Plasma THBS1 did not correlate with overall survival, breast cancer-specific survival (BCSS), or distant disease-free survival (DDFS) in the entire cohort.
In HER2-enriched patients, high plasma THBS1 was linked to shorter BCSS and DDFS, acting as an independent prognostic marker.
Elevated THBS1 levels were observed in patients with positive DTCs and associated with poorer BCSS.
High plasma THBS1 specifically correlated with increased brain metastasis in HER2-enriched patients.

Conclusions:

Plasma THBS1 may serve as an unfavorable prognostic predictor for HER2-enriched breast cancer.
Further research is warranted to validate THBS1 as a prognostic biomarker in this subgroup.